HealthCor Management L.P. trimmed its position in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) by 31.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,945,540 shares of the company’s stock after selling 909,673 shares during the quarter. Pacira Pharmaceuticals makes up 3.2% of HealthCor Management L.P.’s investment portfolio, making the stock its 12th largest position. HealthCor Management L.P. owned approximately 4.73% of Pacira Pharmaceuticals worth $95,623,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Granahan Investment Management Inc. MA raised its holdings in shares of Pacira Pharmaceuticals by 12.3% in the 2nd quarter. Granahan Investment Management Inc. MA now owns 188,086 shares of the company’s stock valued at $6,028,000 after purchasing an additional 20,617 shares in the last quarter. Mutual of America Capital Management LLC raised its holdings in shares of Pacira Pharmaceuticals by 15.3% in the 2nd quarter. Mutual of America Capital Management LLC now owns 155,554 shares of the company’s stock valued at $4,986,000 after purchasing an additional 20,606 shares in the last quarter. Mizuho Securities USA LLC raised its holdings in shares of Pacira Pharmaceuticals by 193.8% in the 3rd quarter. Mizuho Securities USA LLC now owns 23,500 shares of the company’s stock valued at $1,155,000 after purchasing an additional 15,500 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Pacira Pharmaceuticals by 14.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 56,610 shares of the company’s stock valued at $1,813,000 after purchasing an additional 7,249 shares in the last quarter. Finally, United Services Automobile Association raised its holdings in shares of Pacira Pharmaceuticals by 10.9% in the 2nd quarter. United Services Automobile Association now owns 127,822 shares of the company’s stock valued at $4,097,000 after purchasing an additional 12,600 shares in the last quarter. Institutional investors and hedge funds own 97.84% of the company’s stock.

In other Pacira Pharmaceuticals news, Director Andreas Wicki sold 14,527 shares of the firm’s stock in a transaction on Thursday, December 13th. The shares were sold at an average price of $46.84, for a total transaction of $680,444.68. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Lauren Bullaro Riker sold 1,000 shares of the firm’s stock in a transaction on Friday, November 2nd. The stock was sold at an average price of $54.35, for a total transaction of $54,350.00. Following the transaction, the vice president now directly owns 11,474 shares in the company, valued at $623,611.90. The disclosure for this sale can be found here. Insiders sold a total of 165,748 shares of company stock worth $8,083,591 over the last ninety days. Insiders own 5.90% of the company’s stock.

NASDAQ PCRX opened at $45.26 on Friday. The company has a current ratio of 8.66, a quick ratio of 7.83 and a debt-to-equity ratio of 0.95. The firm has a market capitalization of $1.86 billion, a P/E ratio of 251.44 and a beta of 1.65. Pacira Pharmaceuticals Inc has a 12 month low of $26.95 and a 12 month high of $55.00.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its earnings results on Thursday, November 1st. The company reported $0.31 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.40. The firm had revenue of $83.45 million for the quarter, compared to the consensus estimate of $79.87 million. Pacira Pharmaceuticals had a negative net margin of 1.30% and a positive return on equity of 2.74%. The company’s revenue was up 23.9% on a year-over-year basis. During the same period last year, the firm posted $0.11 EPS.

PCRX has been the topic of a number of analyst reports. Royal Bank of Canada set a $55.00 price objective on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, September 19th. Canaccord Genuity set a $49.00 price objective on shares of Pacira Pharmaceuticals and gave the company a “hold” rating in a report on Tuesday, October 2nd. Stifel Nicolaus initiated coverage on shares of Pacira Pharmaceuticals in a report on Thursday, September 13th. They issued a “sell” rating and a $41.00 price objective on the stock. ValuEngine lowered shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, September 11th. Finally, Bank of America raised their price objective on shares of Pacira Pharmaceuticals from $46.00 to $48.00 and gave the company a “neutral” rating in a report on Wednesday, October 10th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $53.76.

TRADEMARK VIOLATION NOTICE: This story was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2018/12/16/healthcor-management-l-p-has-95-62-million-stake-in-pacira-pharmaceuticals-inc-pcrx.html.

Pacira Pharmaceuticals Profile

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Read More: What is a conference call?

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.